logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2018 – Treatment benefits of abiraterone for men with hormone sensitive prostate cancer similar in high and low tumour load

An analysis of the STAMPEDE trial showed significant increases in overall survival and failure-free survival with abiraterone in metastatic prostate cancer, irrespective of the patients' risk